• HOME
  • RESEARCH
  • PEOPLE
    • Matthew S. Davids
    • Current Lab Members >
      • Christine Ryan, MD
      • Stephen Chong, PhD
      • Fen Zhu, PhD
      • Johannes Hildebrand, MSc
      • Mary Collins, BS
      • Liam Hackett, AB
    • Alumni >
      • Charles Herbaux, MD
      • Rebecca Valentin, MD
      • Timothy Lehmberg, B.A.
      • Stephanie Grabow, PhD
      • Simon Husby, MD
  • PUBLICATIONS
  • JOBS
  • SUPPORT US
  • NEWS
    • Awards and Recognition
  • CONTACT
Davids Lab - Translational CLL Research

The Davids Lab
TRANSLATIONAL CLL RESEARCH

2020 Highlights


Picture




​Congratulations to Stephen Chong on receiving a 2020 ASH Abstract Achievement Award for his work titled "Re-Wiring BCL-2 Family Anti-Apoptotic Protein Dependencies through Modulating Phosphorylation to Re-Sensitize Venetoclax-Resistant Lymphoid Malignancies to BCL-2 Inhibition." This is the third year in a row where a Davids Lab researcher has won this award! Check out our Awards and Recognition page for more information.



Picture


Congratulations to Dr. Davids on his promotion to Associate Professor of Medicine at Harvard Medical School and his appointment as the Director of Clinical Research for the Division of Lymphoma at Dana-Farber!















Check out Charles Herbaux's interview with @lymphomahub discussing a recent multi-center clinical trial!

Did you miss the @lymphomahub interview with @Charles_Herbaux, @CHU_Lille, on the results from the phase II trial evaluating the combination therapy of atezolizumab, obinutuzumab, and venetoclax, in patients with R/R DLBCL? Watch it here https://t.co/mdcRYQxdLH #lymsm #ASCO20 pic.twitter.com/fMSvpsD089

— Lymphoma Hub (@lymphomahub) August 16, 2020

ASH 2019 (Orlando, Florida)

Our collaborator, Jennifer Crombie, MD, presenting one of the clinical trials the Davids Lab was involved with.
Charles Herbaux, MD, presenting his oral abstract on apoptotic dependencies in T-PLL . He received an Abstract Achievement Award for his work.
To learn more about this study, click here.
To learn more about this study, click here  

ASH 2018 (San Diego, California)

Rebecca Valentin, MD, presenting her work on the SRF231 antibody and its activity against CLL.
Tim Lehmberg, BA, presenting his work using BH3 profiling to predict patient response & MRD status.
To learn more about this study, click here.
To learn more about this study, click here.

Watch Dr.Davids' interview at the WEEI NESN Jimmy Fund Radio-Telethon here!

  • Huffington Post:  Scientists Raising Their Own Funds For Cancer Research
  • Boston Magazine:  For This Dana-Farber Doctor, the PMC Is More Than a Bike Ride
  • ​Boston Business Journal:  FDA approves 'game changing' leukemia drug developed at Dana-Farber
  • DFCI ​Paths of Progress:   Breakthrough Therapy:  New Drug Causes Cancer Cells to Self-Destruct
  • CBS Boston: Cancer Doctor, Pan-Mass Challenge Rider Sees Fundraising Results Firsthand
Follow Dr. Davids on Twitter:  
          
Tweets about @DrMDavids
 HOME | RESEARCH | PEOPLE | PUBLICATIONS | JOBS | SUPPORT US | NEWS | CONTACT 

©2016 Translational CLL Research at Dana-Farber Cancer Institute